Skip to content
Pulmonary Embolism episode artwork

Dec 1, 2017 1 hr

Pulmonary Embolism

from Take Aurally Hosted by Take Aurally

Dr Harry Pick Respiratory SpR and researcher extraordinaire joins us in this bumper pod to talk through pulmonary embolism, its diagnosis and management. Be prepared for a lot of Evidence Based Medicine - the best kind of medicine! For more information please visit www.takeaurally.com. We're also on Facebook and Twitter. NUH DREEAM can be found on both Facebook and Twitter.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Pulmonary Embolism

0:00 1:00:26
of matches

Transcript Auto-generated, may contain errors

Thanks for downloading and welcome to Take Orally, the emotive medicine podcast recorded at Dream Queen's Medical Centre at Nottingham. In this episode we'll be discussing pulmonary embolism. As ever, all information is correct at the time of recording. All guidelines mentioned are correct for Nottingham University Hospital's NHS Trust. Other trust guidelines may vary. All views and opinions are the speaker's own.

Hello everyone, welcome back to Take Aurelie. Jamie Thomas here, teacher fellow in emergency medicine, and I'm delighted to once again be joined by Harry Pick, respiratory physician, registrar and research fellow. That's great, thanks Jamie. Thank you for coming once again, Harry. And we're now going to tackle, as we've all just been talking about before we started recording, one of my nightmare diagnoses, pulmonary embolism or PE. Yes, yeah. A difficult diagnosis, one that doesn't always play fair, as we're going to discuss, and one not to be missed, I think that's fair to say. Yeah, so I think a challenging diagnosis at times.

It's not always textbook, as you read. You don't always come over the things you expect. And it has quite a high burden of disease for patients, significant mobility, mortality, and something not too necessary to be considered whenever you're seeing patients that present through ED with chest pain, shortness of breath. collapse the things we're going to discuss. Yeah, so I mean whenever I say to a medical student to talk about PE, they will mention DVT, they will mention young lady on the pill, a recent long-haul flight, a pleuritic chest pain, shortness of breath, they have a very barn door image in their mind but I think that's not always the case. Yeah, no, so I think probably half the time it is but I think half the time it's probably something that creeps up on you, you're not necessarily thinking of it straight away, is there any differential and then sort of hits you either because you find it by scanning them or you find it because they get worse and you have to find it or unfortunately they pass away and it's a post-mortem diagnosis which comes as a shock as well. So here we're going to talk through some of the stuff I know about PE.

stuff I've got together again since I've been asked to do this a lot of stuff's taken from some of the most recent international guidelines so got the BTS PE guideline from 2003 the NICE-VTE guidance from 2012 and the European Society of Cardiology guidance from 2014 along with the NUH local guidance sort of crammed in there for good effect so I suppose the first question is ultimately most important you know what is a PE what is DVT and PE, so deep vein thrombosis and pulmonary embolism, come under the hat of venous thromboembolic disease. And that's basically clots forming in your venous system, either staying locally within your leg and causing signs and symptoms of DVT, or embolising, travelling off to the lungs and causing their own problems there. And the three things needed really, and this is sort of an underlying biological principle for clotting, so abnormal thrombosis, which is what DVT and PE is, is abnormal blood, abnormal flow, and abnormal vessels. So it's something within those three that's causing you to then have these problems. Velocop's triad. Velocop's triad, yes. Yes. That's extra points they're doing. So that triad is...

you generally have to have something within that triad that's causing you to then be predisposed to the form of thrombus either in the leg or in pulmonary embolism. So just a bit of background stats for you. Awesome. presentations for PE I think we all think of the symptomatic patient coming in with pleuritic chest pain after they've been on holiday to some far-flung destination but actually quite a lot of PE's are asymptomatic now either being found as an incidental finding on the CT scans we're doing for more and more reasons you know cross-sectional imaging and the significance of those are debated especially if they're small segmental whether we need to do anything about them or not symptomatic ones that we look out for and we catch but then actually people just dying from their PEs and it being a diagnosis afterwards, you know. So there's a study in 2004 that across 60 EU countries found there were 317,000 deaths from PE in a single year. 34% of those presented a sudden fatal PE to medical services. 60%, just under 60%, were a post-mortem diagnosis. And only 7% of those that died, were a diagnosis made pre-mortem. So they were diagnosed and treated. So actually you're looking at over 90% of people with PEs who died in that cohort, presented either too late or died and then were found afterwards. So you just need to be aware that we don't always pick it up and it should be there in the back of your mind, something to think about.

One of the things that struck me as well when I was reading through some of the guidance was, I'm not sure about you, Joe, but I think of it as a condition that's usually people, I think of it most often in middle age, not particularly elderly patients who come in with pleuritic chest pain who've been away or they're on the pill or something else. But actually, the risk of PE increases with every decade. If you're under 40, you have a lower risk than anyone over 40. But for every decade after that, your risk doubles. So if you're 50, your risk is twice that of a 40-year-old. If you're 60, it's four times that of a 40-year-old. If you're 70, it's...

eight times that of a 40-year-old. So actually, as you get older, the risk is higher. And I think that's something that surprised me. And looking back on the cases where I've missed PE or I've not considered it, it probably is those more elderly patients who come in, multiple non-specific complaints, where actually they have a higher risk. So it's something to spare in your mind. Is that because, I mean...

Do we know? Is that because as you get older, you're more likely to develop AF, or you're more sedentary? Is it all those sorts of things? I think it's probably multifactorial, a combination of abnormal vessel, abnormal flow, abnormal blood, from the reasons you've just said. So I think there's no definite reason, but there's definitely that association for cohort studies. So moving on from me to talk about the risk factors. The way I classify them as patient-related, and they're usually permanent risk factors. And then the setting-related, which are usually temporary. So if you're looking at patient-related, it's things like age, their comorbidities, the non-reversible ones, such as malignancy. And then also the history, personal or family history of DVT or PD.

and they're looking at the sort of setting-related, these are usually temporary things, so they've had lower limb surgery within the last four weeks, they've been involved in trauma, immobility resulting from either of those, pregnancy, oral contraceptive pill, HRT, and so pregnancy was interesting for me. You always know there's an increased risk in the peripartum, either antinatal, postnatally. A pregnant woman who's just delivered is 60 times more at risk of PE than a non-pregnant woman for the three months after her delivery. So that's really quite a risk. even afterwards for three months. Yeah, and it's because of the activation of cytokines, inflammatory cascade, you know, body repair, hormone changes, all of those things that are going on in that postpartum period. But yeah, 60 times increased risk in the three months following their delivery. Shows the value of a very good history, doesn't it, thinking these things. It's not always something you'd think of if, you know, someone comes in short of breath and they're, you know, three months is 12 weeks, they're 10 weeks down the road from their delivery. That's not something you're generally asking, but if they haven't got a baby with them or a partner, you know, there's not signs of being in that nursing period. So it's something you should always ask, I think, something we'd probably miss. Excellent. Okay, so...

So we've got our risk factors that we're thinking about here as well. So I suppose, shall we sort of work on towards the presentation of our patient? Because, you know, I really wish they would walk in with PE written on the forehead. As I've often said on podcasts, it'd be great if they walked in with a diagnosis. And sometimes they do. They've Googled themselves and they said, I've got this. But have you got any data there about, you know, the presentations of patients with PE? Yeah, so it's interesting. So obviously your clinical approach, these patients, ED, especially Bioskis, anything we're doing in medicine, A, B, C, D, performance, forefront of your minds, you know, adverse features.

respond, diagnose appropriately. Once you've got past your ABCDE and you're happy that you've got the time, the luxury to talk to them, you're looking for those clinical features. And the study done by Pollock and colleagues in 2011 looked at pulmonary embolism diagnoses in patients presented to ED. And so they had just under 2,000 patients who were diagnosed with PE and compared them with 500 who didn't have PE. And unfortunately, they don't always come in with what you want them to. So in that study, they showed that only 50% of patients with a confirmed diagnosis of PE presented with dyspnea, so shortness of breath. So that was their reason for coming in and short of breath, yeah. Only 40% of them presented with pleuristic chest pain. 25% of them presented with signs or symptoms of DVT.

8% of them presented with hemopsis and 6% of them with syncope. And actually those specific clinical presentations taken in isolation for a diagnosis of PE have a very poor sensitivity and specificity. And I think that's probably counter-intuitive to what you and I... think of when you think of PE you know you think of that textbook definition of somebody's been on holiday or on the oral contraceptive pill walking in with this agonising pleuristic chest pain and they're panting and they're sat alone and then you know big swollen cough and it's all there together isn't it yeah ready to accept your professorship from the local medical school next to diagnosis but actually the natural history is they don't present with those things yeah and that's what makes the clinical prediction rules that we use within medicine for PE even more valuable and we'll come on to talk about those sure um i suppose one of the things in my mind i do so i've taken the history uh i've asked about those clinical features and then trying to think about risk factors so i'm asking the questions both to satisfy the clinical risk prediction scores that we're going to talk about, but also to see if there's any underlying pathology that we know of. I suppose my mind is trying to think about, from their presentation, what they told me, I think it might be a PE. How am I going to approach this patient, and what do I need to do immediately, and what can I wait to do? And I suppose now it's looking to see whether it can be, I suppose, what we call a massive PE or a submassive PE. So massive PE, as you'll know, is somebody who's very unwell with their pulmonary embolism. They've probably got evidence of right heart strain if you do an echocardiogram or a CT, but their hallmark is they prevent with persistent...

shock you know hypertension and the national national guidelines say that you have to wait for systolic blood pressure less than 90 for more than 15 minutes And if you're getting into that situation, or they're peri-arrested, or they've arrested, then you need to treat them as a massive PE. You need to be thinking about thrombolysis, and also an urgent imaging of some sort, whether that be a bedside echocardiogram, if they're not stable enough, or a CTPA, if they are. And then proceeding on that avenue. And then the other side of that is someone with a submassive PE who's got the symptoms we've described, or maybe a non-specific presentation, but they're not unwell acutely. They don't need immediate intervention within the next 10, 15, 13 minutes. You've got a bit more time to work out what's going on. So it's hemodynamic stability, basically. Exactly, yeah. That's the hormone, cardiorespiratory stability. Yeah, exactly. So, I mean, whenever I talk to students as well, I mean,

There are some ECG features that you can see in PE as well. And students always, you can tell if they've done a bit of reading, jump up and go, you know, S1, Q3, T3. It's rubbish, isn't it? Yes, it is, yeah. So the ECG, the commonest abnormality in pulmonary embolism is just a sinus tachycardia. Yes. So, again, take that into account. You can get non-specific ST and T wave changes, and often either a left or right bundle branch block, more commonly a left, but any of those features. I've seen patients with ST elevation that have turned out to be pulmonary embolism, ST depression. So it's part of the pathology, pathophysiology of pulmonary embolism. If you've got a large PE, you get significant...

back pressure on your right ventricle. And there is evidence that even people with patent coronary arteries can have right ventricular myocardial infarction as a consequence of their pulmonary embolism. So therefore they can get SD changes that are associated with that as well as the pulmonary embolism itself. And that then complicates management and their outcome for that is normally very poor. So we've taken our history, we're thinking PE, there's a little voice in the back of our mind. I remember that podcast I listened to when I was in med school with Harry.

Our clinical suspicion is up, but we've got some stratification tools, haven't we, brilliantly, so shall we talk about them a bit now? Yeah, so the most commonly used, most widely known, will be the WELLS score. There's several versions of it now. So initially developed for DVT, and another version for PE, and then there were the simplified versions for both DVT and PE. So the old WELLS score used to be a three-level score, which gave you a score based on risk factors and presenting features of either low probability, medium probability, or high probability.

Fortunately for people like me, it's been simplified. And people like me. It's now a two-level score where you either are low probability or high probability, and we'll come on to what that means for you in the long run. But the two-level score is looking for clinical features, but also risk factors which would then push you down an avenue of QMP. So it's looking for clinical signs of a DVT, which would score you three points, the PE being the most likely diagnosis. It's not worded quite like that.

an alternative diagnosis is not as likely as PE. It's just a double negative city, it confuses the hell out of me. It's equal or most likely PE. So it's that clinicians gestalt, isn't it? I think this is... And actually in the papers where they validated these, that is the most, that is the factor that's got the most interobserver...

discrepancy. So when we're comparing two people looking at the same patient, the bit, whether it's the biggest variation in what people call, is it the most likely diagnosis or not for PE, is that scoring of something that's more likely or less likely. But that gives you three points if you think PE is the most likely diagnosis. So it scores the most. Yeah, exactly. So your gut, your gut there, nothing else saying there's something else. I don't know about you, sorry to interrupt, but I think I've seen it as well, people who maybe haven't thought of PE, if they're telling the history, if somebody else goes, oh, what about PE?

Oh yeah, now you've mentioned PE and it's difficult. Yeah, definitely. I would put PE on the bottom of most of my presentations to ED for that sort of category in terms of chest pain, shortness of breath, syncope, haemoptysis. PE would be there for most of them. And then anything that you can't explain, I'd stick PE on there as well. Because it's just one of those buggers that comes and gets you. So science DVT gives you three. PE most likely gives you three. Heart rate of over 110 gives you one and a half. Immobility for greater than three days or surgery within four weeks gives you one and a half.

A previous episode of venous thromboembolism, so DBT or PE gives you one and a half, hymopsis one, and a history of malignancy one. Within the malignancy, it's if they're on palliative treatment, so they've not had any intervention, they're on active treatment at that moment in time, or they've been treated but within six months. So if you've got somebody who's had breast cancer 10 years ago and they're in remission, that wouldn't count. If you've got somebody who's coming from nursing home who's actually got lung cancer but not for any active intervention, that would. And you're adding those up, and if you've got a score of less than four, it says that PE is unlikely, and you've got less than 10% probability of having a PE subsequently if you're less than four. And a score of...

four or more makes PE likely, and you've got a 70% chance of having a PE if you score that high. So you've got a less than 10% chance, you've got a 70% chance on the other. Exactly, yeah. And that sort of informs what you need to do next. Sure. So this is where it gets interesting. So the Wells score would say, if you've got a score of less than four, PE is unlikely you should progress to do a D-dimer. Sure. A D-dimer is the bane of every medical emergency medic's life. Who ordered the D-dimer? It's a well-known complaint. So D-dimer, as you'll know, is a non-specific test.

But it has got a very good negative predictive value in pulmonary embolism, or venous lumbarism, embolism in general. So if I stub my toe, my D-dimer will go up. If I have a few too many beers, my D-dimer will go up. If I have a stroke, my D-dimer will go up. If I have an infection, it will go up. If I have pulmonary embolism, it will go up. But a negative D-dimer in the context of suspected ET is very reassuring. And actually, the probability of you having a pulmonary embolism, if you are low probability and have a negative D-dimer, is less than one in a couple of million, actually. It's very, very low. So it's very reassuring. Unfortunately, if they have a positive D-dimer because they've actually got chest infection, you then end up having to do a scan of some sort to confirm or refute that diagnosis in the low risk patients.

or low severity unlikely and i think we're still i mean you'll know more about me in this but we're still at this stage of it's either negative or positive the d-dimer i mean so even if it's one over the upper limit that is a positive is that still where we're still yeah so you have to be you have to take into account that the d-dimer was developed and validated in a cohort and 500 or 0.5 depending on the system you're using was taken as a figure because it gives you the best sensitivity and specificity and negative predictive value so 501 is still by the textbook a positive and i've had this conversation with many a doctor before saying well it's only 503 it's nearly negative let's kick him out and actually No, it's positive for a reason. They still have a risk. And there isn't any quantification between 503, 5003, 5003 between their likelihood of a PE. In practice, the patients who have the highest D-dimers nearly always have a VTE and or some underlying diagnosis of malignancy. But I've seen people who've had negative D-dimers who then have gone on to have a positive scan because of clinical suspicion. I've seen people with borderline D-dimers who then... So the absolute value isn't as important as above or below you're cut off.

And for those people with a score of greater than four, doing a D-dimer is worthless, save the trust of money, and save it for a scan. I read a paper that if you have, people with a PE have had high wells above four, 5% of those patients will have a negative D-dimer. I'd say that reflects my clinical practice as well. So actually you've got a very high risk group, like you said, 70%, you've got this high risk group, and 5% of them will actually have a negative D-dimer. So if you've got that high wells, you've got that suspicion of doing the D-dimer, A is, you know, a necessary waste of money.

but actually you're putting some patients in danger because you could be falsely reassured. Exactly, exactly. So it doesn't add anything to your diagnosis. It's got no benefits. And if you do get it in your reassuring discharge and seven out of 10 of those people, they may collapse or have further illness because of it. And so the interesting thing for me is, I don't know whether you've heard of the PERC rule. I have, yes. So I like the PERC rule because it means I don't have to do things to patients. So if you've got someone who's low probability, so low risk, either on the well score or from your own clinical judgment, you can apply the PERC rule to them. And if they have none of the PERC features, so they're all negative.

you can discharge them without any further investigations. That's PERC, P-E-R-C. That's right, yeah. So the PERC includes, so to be negative, you have to be age under 50 years, a heart rate of less than 100, SATs of greater than 95, no haemopsis, not taking the oral contraceptive or HRT, no surgery or trauma in the preceding four. weeks, no venous thombo-amnism history and no clinical signs of DVT. So for me, like you said about the ambulatory care patients, if you're in ambulatory care, you've got someone who's low suspicion, they've probably got a viral chest infection, some pleuritic chest pain, low risk on their well, so you do the PERC, they're 40, they've got those other signs there, fine, no need to send off a D-dimer, no need to scan them, reassure them, send them home. They've got less than a 1% risk of then having primary amnism and becoming clinically significant. So if they're low wells and also zero on the PERC, brilliant. That's something you can not investigate further, reassure, obviously give them safety netting advice, counsel them if things deteriorate or persist, they should go back and see somebody. But you can be relatively reassured by that.

But like you said, you only need one of those. You failed the PERC. And therefore you need to go back to doing a D-dimer if they're low, but they should be low, so doing a D-dimer and investigating them. So either if we've got our patient who was low wells, but their D-dimer's positive, or they're high wells, so we're now suspicious of PE, how are we going to confirm our diagnosis? So it's a good question. So imaging is the answer. And there's the old CTPA versus VQ. So CTPA is a CT, pulmonary angiogram, or angiography, and VQ is ventilation perfusion scan. And the main difference is availability in and out of hours.

but also radiation exposure. So the majority of patients you encounter will end up having a CTPA, usually because of the validity of the scan, clinician preference, because it also helps you think about other things if it's not a PE, and also because there isn't a reason not to do it, if that makes sense. So a CTPA, they normally need a decent-sized scan, you're in a decent-sized vein, it's a contrast media that's administered, the phase of the CT that catches the pulmonary arteries, and then you can see whether there's any filling defects on that. Normally takes about... 15 minutes to type in your request, an hour or so to happen, depending on which site you're at, maybe a couple more hours if you're in ED, and more hours than that if you're on the medical wards, and then maybe half an hour to get a report back. The VQ tends to be something that you bring patients back for in working hours, Monday to Friday, 9 to 5. They often have to have a couple of days of treatment prior to that. But the VQ is a good alternative for people who've got a contrast allergy, who've got renal impairments.

If they're young with a normal chest x-ray because they can get a lot lower radiation dose, it's the preferred investigation of pregnancy. It's also something to think about in people with haematological malignancies like myeloma, parisproteinemia, because there's always a risk with those patients giving them contrast that they've already got impaired renal function from their myeloma that you may not put their kidneys off. That's something to think about for them. And in terms of radiation, CTPA conventional, the newer ones, is about 2 to 6 millisieverts. And the VQ scan, depending on whether you've got to do the ventilation side of it, is between 0.6 and 1 millisieverts.

a bit of radiation difference depends on the age of the patient if you've got a 25 year old so you're going to be doing a CTPA that's not an insubstantial amount of radiation someone who's got another 60 years to deal with the effects of that there's someone who's 80 it's probably less of a problem in terms of their lifetime risk of malignancy after that there's something to have in the back of your mind to think about yeah the majority of people have a CTPA I suppose it's worth thinking if you have a young lady, breast tissue, exposure to radiation, et cetera. And actually, I've got some notes on pregnancy, so we'll talk about that at the end. And specifically pregnancy, VQ versus CTPA, and I'll go through some of the radiation stuff that comes around as well. I mean, you mentioned doing a chest x-ray for VQ. I think, I mean, chest x-ray for me, I mean, for this trust here at NUH, the radiologist here in AD wanted the chest x-ray before we even do the CTPA. But I find that's very useful, even if I haven't thought about PE. If, say, you've got a history of asthma or COPD, so that's my primary thing. But if you've got a clear...

chest x-ray, if you have got clear evidence that you're desaturating, if there's a big AA gradient, say, on your ABG, but I'm not seeing it on a chest x-ray, that blend PE then comes into my mind as well, if it hasn't been there before. Yeah, it's almost a prompt, isn't it? I think in your work, if any of the presents, with shortness of breath, chest pain, your investigations are your usual bloods, FPC, UE, CRP, LFTs. I think you need to be able to assess them, but also then manage them safely. ECG, doing the SATs, doing their peak flow, a lot of chest x-ray.

For me, it goes without saying. It's almost as if they haven't got a chest x-ray, they're not really going to be seen by a respiratory doctor yet. But yeah, it definitely needs it. And it also gives you that weight to say, when you're talking to a radiologist at 3 a.m., to say, I really want to see TPA now because of this, this, this. When you say actually the x-ray is completely normal, there is nothing to see on it. It gives you that extra weight, as does actually having an area of wedged state infarct on an x-ray, some consolidation, like a pneumonia, but there's a very distinct triangular pattern tapering in towards the medial aspect and out towards the lateral. It just gives you that evidence to then say.

PE, let's get back on. And like you say, it acts as an aid man wilder, someone who you think might have a chest infection, oh, their x-ray is completely normal. What else would give them that with a completely normal x-ray? Have you ever seen Wedge Impact once? And they did have a PE though. I was very proud of that point. And I think just before we move on to the management PE, that's talking about the SATs. And I mentioned it before on an asthma podcast. Patient comes in with shortness of breath. They sit on a trolley in A&E or on a ward for hours and hours and hours. Of course, their SATs could very well be normal. Get these patients up, put the SATs probe on them, walk them a bit, see are their SATs still okay after just walking a few yards. I think that's very useful diagnostically. Yeah, it's something I routinely do.

pulmonary embolism patients, but anyone who's coming through an ambulatory care area or acute medicine, you're remembering and hiring about whether it's safe to send them home or whether they need admitting, you know, if there's no other adverse risk factors or other signs, actually just get them to do a couple of lengths of the corridor with a SATs machine, either with yourself or a friendly nurse, if you can rope one in to do it, just to see whether they desat or not. It just gives you a nice indicator of, you know, whether they can safely go home or whether they need to stay in for some more investigation. And like I said, if you've been sat in a trolley in ED, you know, middle of winter, been there three hours, 59 minutes, you're trying to make a decision, you know, you've got to get in and find out what's going on. Absolutely. So...

I think it's also worth pointing at this point, here in our emergency department as well, if we have booked the scan, we're thinking PE, it's on top diagnosis now. If we have booked the scan, we also treat. So they've had their anoxaparin dose before they go and have the scan because they can be waiting for a while. And that's something we do here in the emergency department to treat beforehand. So the national guidelines are, if they are hemodynamic compromised, obviously get on a treat, confirm diagnosis, azkylidate thrombolyse. If they are suspected, then...

There are options about that, and I can see why people take the pragmatic approach of giving the anticoagulation versus not. The guidelines are, if you're going to have the CTPA within four hours, then you can wait and you don't have to give anticoagulation. If it's going to be four hours or longer, you should anticoagulate and then let them have the scan. And often, like you say, you need department's wards. It often is on the borderline in four hours or isn't going to happen, you're not sure. It's probably safest in the overwhelming majority of people to give the anticoagulation. A single dose of 1.5 milligrams per kilogram of amoxaparone is what we use locally. And the risks with that are relatively small. Take your usual history in terms of bleeding risks. Have they had a recent GI bleed? Is there any intracranial pathology? Are they on concurrent anticoagulants? Those sorts of things that you just need to be thinking about. Have they had recent surgery within a couple of weeks? Just to make sure you're not going to cause more harm than good. In the overwhelming majority, the best thing to do is give them the treatment and wait for the scan. So now moving on then to the management of PE. Yes.

the key bit, really. That's really divided up, I suppose, into the presentation of the patients, so whether they have, as we've already talked about, is it a massive, is it peri-arrest or in-arrest versus this sub-massive group. Yeah, exactly. So you've got your confirmed diagnosis by whichever route you've got to that, so you know you've got PE. So something quite useful to do is calculate an S-PESI score, so P-E-S-I, that's a simplified PESI score, and that gives you an indication of their likely prognosis, and that's based on age, whether they've got cancer diagnosis, heart failure or chronic lung disease, heart rates are greater than 110.

pressure less than 100 and arterial saturations of less than 90 and if you score zero on that you have a one percent 30-day mortality and if you score greater than one you have a 10 to 11 percent 30-day mortality and the benefit for that is if you're in the emergency department you've got a confirmed diagnosis there's no other adverse features they score zero on their S-PESI they should be there's also clinical judgment comes into this appropriate for anticoagulation and outpatient management and follow-up whereas if they score one or more they'll be the patients you want to admit to to medicine to be reviewed and managed and their anticoagulation started so going back to what you're saying about classifying patients and their management so Firstly, let's take massive PE. So you've got someone who's got evidence of cardiorespiratory compromise, hemodynamic instability, systemic blood pressure less than 90, peri-arrest or having an arrest. The guidelines would say...

Decent bilateral IV access, A2E assessments, supplemental oxygen. If needed, they can be intubated and ventilated. But actually a lot of the evidence says that doing that causes instability. So there's a problem with giving the anaesthetic drugs you need to intubate, which will contain hemodynamic compromise across all conditions. But there's an added, when you're ventilating, the changes in intra-thoracetic pressure associated with that can actually worsen the decompensation, the RV strain, and it can actually cause them more harm than good. In the overwhelming majority, giving supplemental high-flow oxygen is often enough as a holding measure to then see them through to whatever treatment they need to keep their SAT to about 92, 94.

IV fluid challenge is something I've seen people do differently in these patients. The old model used to be you gave quite a lot of fluid quite quickly to try and help boost their cardiac pressures and see whether that would help. Actually more recent evidence shows that over a litre of fluid can be harmful. So the guidelines currently say give 500 mils as a stat bolus over sort of 10 or 15 minutes. See if you bring their blood pressure up, help with their contractility, help with their stability, but actually more than that probably isn't necessary. And then there's always things like vasopressors if you've got persistent hemodynamic compromise. Most commonly is noradrenaline. There is evidence for dobutamine or dopamine infusions as well, but noradrenaline is the one we're most familiar with.

And then the real thing they need is reperfusion therapy as soon as possible if they're in that category. So the one we will be most familiar with is thrombolysis, which will be pharmacological thrombolysis. Usually has to be given through a relatively large cannula or central line if possible, although they don't want you to put central lines in non-compressible places. So a large cannula usually suffices. You often need a couple because you have to run heparin along through with the alteplase.

um and i suppose what we use locally it's the most uh most commonly used tissue collagen activator uh and the dose of that depends on whether they've got imminent cardiac arrest or incardiac arrest or whether they're just stable your local trust guidelines will tell you the exact doses it's between 10 and 50 milligrams as a bonus followed by infusion alongside iv heparin usually And quite interestingly, the national guidelines and the local guidelines all say that we should try and consent patients to thrombolysis. So we should, wherever possible, approach them, explain the risks and benefits, and then get their permission, whether that's verbally or on a signed consent form, which I think is actually something easier said than done. Very much so. Very poorly patient. Yeah, and often maybe actually consent by proxy, so speaking to a family member who can, you know.

agree to treatment, although if they disagree, we'll probably crack on them anyway. The ethics around that, we can discuss another time. But interestingly, the quoted risk of intracranial hemorrhage is more than 1 in 100, but less than 1 in 1,000. So it's probably more like 1 in 200, the risk of intracranial hemorrhage, somewhere along that. And the risk of significant GI bleed is probably greater than 1 in 100, but less than 1 in 10. So it's probably around a 1 in 20, 1 in 30 risk of GI bleed with thrombolysis. So that's just something to have in your back of your mind. Yes, it's a PE. Well, it might be a PE. Yes, it's confirmed on ECA or urgent CTPA. I'm going to give this, hopefully, make it better, but there is a risk for other complications.

And the things to consider when trying to think about thrombolysis, the absolute contraindications are hemorrhagic stroke, an ischemic stroke within six months, CNS trauma or malignancy, recent trauma surgery or head injury, and that's defined as less than three weeks, a significant GIB within the last three months or any bleeding disorder. And I'd probably put into that uncontrolled coagulation disorder due to one of the pharmacological agents. So vitamin K antagonists, direct oral anticoagulants, a lot of people would avoid thrombolyzing those sorts of patients. In stroke now, they are starting to thrombolyse it in studies, patients who are on oral anticoagulants, to try and get the evidence to say that it's safe, but at the moment we don't have that for P and it's not a licensed indicator. Sure. A lot of the other things that you think about as sort of relative contraindications is at physician discretion. So that's things like surgery longer than six weeks ago or abdominal wounds, you know, those sorts of things where you just, you'd second guess yourself a little. The one that isn't done on here, interestingly, is thombocytopenia, but I suppose it comes with bleeding disorders and anything under 17, I'd probably be hesitant to definitely be speaking to a hematologist for anything under 100 just to say, there's this patient, you know, I want to thombolise them. What do you think about this? What's your advice? Just to, one, protect yourself, but also protect the patient.

And interestingly, when you get thrombolysis, the haemodynamic effects from that, so the resolution of the hypovolemia or haemodynamic instability, will last about two to three days, but there's no sustained effects beyond seven days. And the greatest benefit to giving thrombolysis is giving it within the first 48 hours after symptom onset. But you can give it up to 14 days later, so within the first 14 days. So if you've got that patient who comes in and says, oh, I flew home, I've got crushing pain, it's been there for six hours, they've got a low BP, they've got a PE, they will get the basis benefit given straight away. But if you've got someone who comes in and says, I flew home two weeks ago. I've had this niggling pain since then. I've been a bit short of breath. Actually, I've got a massive PE. As long as it's within the first couple of weeks, you can still give them. According to the guidelines, obviously, you're also using cardiac arrest and you've got nothing to lose. The majority of people would get thrombolysis as a last stitch. If you are in that arrest situation and you've given thrombolysis, the Resuscitation Council guideline would be that you continue resuscitation for at least 60 minutes to give thrombolysis a chance to work and to make sure you're not stopping it. So in A&E, that's when we get the Lucas machine out. Because otherwise, getting staff to do an hour of CPR is... They don't need to get to the gym for a few days. Yeah, they don't need anything. Yeah.

I remember the last arrest you'd appear and it is, you know, after play is, when you say anticoagulate, it anticoagulates it. The blood is like water afterwards because we were gangulating afterwards. But yeah, the Lucas for an hour. Yeah, yeah. And one of the relative contraindications, as you alluded to, is lines, central lines or...

non-compressible sites of trauma because like you say it just pours out if you have any and one of the things to always do just a practical tip is try and pop in a catheter before you get thrombolysis so you're in your catheter just because if you're burning afterwards there's a risk of trauma and obviously you're going to want to monitor their hemodynamic status you don't want to know what their kidneys are doing especially if you had to give them a contrast for a CT they've had a prolonged period of hypertension you'd always be worrying about their kidneys as well so you want to see all the urine out there but try and do that don't let it stop thrombolysis but if you can crack it on and get it early in the assessment it does help in terms of not causing traumatic bleeding hematuring And so another option, depending on local availability, is either local catheter-directed thrombolysis. So central access, normally through a femoral artery or vein, getting up to the site of the embolism and then giving a locally administered thrombolytic agent. Some trusts you have availability, sometimes it's within working hours of interventional radiology, other trusts there's no access to that sort of thing. So that would be very much up to your local service. And then there's always surgical embolectomy. So thoracic, cardiothoracic surgeons, cracking the chest, going in and removing the clots surgically.

It tends to be done in patients who have significant contraindications to thrombolysis, but who are well enough to undergo surgery. And actually, if you talk to the surgeons who perform this period, it's not a particularly complicated procedure for them. And I was quite surprised to learn that the perioperative mortality for that procedure is only about 6%. So it's really interesting. It's not something I think we'd always consider. It's not something that's offered locally. But if you're in one of the large centres, you know, Patworth, somewhere like that, the surgery is probably done a bit more often than we do it here. You know, Sheffield, I think, offer a service for it. But if you've got somebody who's got a large intracranial tumour, coming with a PE, and they need intervention, you know, something to think about, then you can talk to local specialists, get some advice.

so moving on to our submassive PE now submassive PE really the staple of our work much higher proportion of our patients have submassive PE compared to you know the massive PE and the thombolysis and the mainstay in submassive PE is anticoagulation yeah and in the most part that initially is with a low molecular weight subcut so an oxpyrin locally dose of 1.5 milligrams per kilogram Different to that is if you have people who are very obese or if you have pregnant ladies, they often give a 1-milligram BD dosing for that just to spread out so you don't get peaks and troughs. And if you're pregnant, it's based on your pre-pregnancy weight. Yeah, so it's your booking weight rather than your 40-week. Yes, we are. And so traditionally, vitamin K antagonists, so warfarin, have been the mainstay of anticoagulation, both for DVT and PE, with the inherent benefits and risks of warfarin. So benefit is we know a lot about it. We've used it for a long time. Disadvantages, as you'll know, multiple interactions, difficult dosing, variable dosing between patients but within patients. Lots of...

potential problems with side effects and interactions, and monitoring for patients in the period of time they need to carry on that escalation. And also the need for bridging therapy, so you'd have to go on your Noxaparin to keep your therapeutic until your RNR is therapeutic for two consecutive days, or for longer than five days, or over the target RNR. Pass that on to the juniors. And the newer agents, so the direct oral anticoagulants, or what used to call the novel NOACs. NoACs or DOACs, yeah. So conventionally, because they're not novel anymore, it's DOACs. So they worked by directly interpreting the coagulation category, normally factor X or factor Xa, and they are usually once or twice daily dosing, no monitoring, give you a consistent level of anticoagulation. Much more favoured by patients and becoming more popular with physicians now, clinicians.

non-inferior to vitamin K antagonists in the treatment of PE in all the studies and possibly safer in terms of risk of GI and intracranial bleeding as well. The only problem or caveat to that at the moment is that for the DOACs, we don't have any, we have one, but we don't have a lot of available antidotes to those. So reversing anticoagulation can be challenging. No one ever thinks of the A&E doctor. Yeah, well, I think we do and we just decide that you give us the trouble. But we'll let you handle this one. I know patients love it because they don't have their INR to check. I mean, that's a major benefit. I know patients say that, they've said that to me.

But, at least with Orphan, you know you've got a reversal agent for errors. I mean, there are reversal agents available. They are very expensive monoclonal antibodies, and they don't get given out quite as easily as a bit of vitamin K or some octoplex. In practice, for the majority of them, the half-life of them is so small that if you stop the anticoagulant, it has a similar effect to giving vitamin K to someone who's on warfarin. The time periods are about the same. It's if they have massive bleeding. There are still things you can do. So blood transfusions, give FFP, give platelets. It reverses them to a certain extent. I think if I had a P, I know what I would have, but it wouldn't be warfarin. I'd have a direct or anticoagulant because the risk is relatively low in me of having a bleeding complication. But I think you're already frequent for those people with other problems on dual antiplatelets as well as this. You have to really weigh up the options of what you're going to do. Absolutely.

Some of them do require bridging therapy initially, some of them don't. Conventionally, locally, it tends to be River Oxban or a Pixban that we use. Divigation is also available and the Oxban is currently being evaluated, so there's plenty of them out there. I don't know if you have any data, Harry, on... people re-embolising on warfarin versus DOACs? Is there any superiority? So, not that I know of. No. The problem with warfarin comes when you have people who have labile INRs. So if they have INRs are either very high, but they're tired or very low, or they spend a lot of time outside their therapeutic window. So there's good evidence that people that spend more than 25% of their time within their therapeutic window have a higher risk of thromboembolism, and that comes from a lot of the atrial fibrillation studies. So if they're always running at 1.8, 1.6, when they should be at 2 to 3, then their risk of clotting on them is higher.

The direct oral anticoagulants aren't licensed for use in patients who read thrombose while they're in treatments. So they're not, if you fail treatment with a direct oral anticoagulant, you then have to go on to either subcut heparin or a high dose of warfarin. Some people using them off label, they are giving double doses of DOAC to those patients, but that is off license. There's not a great deal there that can support that. I would say from my experience, they have roughly the same thrombosis rate when they're on treatments. But again, I don't know the numbers behind that to be perfectly honest with you. Okay, that's fine.

And in terms of duration of treatments, so for all anticoagulants, if you have, whether it's provoked or unprovoked, so whether you've got those risk factors or it's out of the blue, not really sure where you've had it. So a provoked PE, there's a clear risk factor behind it. An unprovoked, you shouldn't have had a PE, but you've had one. So provoked, like you say, is you've been on holiday, you've had a long haul flight, you've got a cancer, you've known to take the oral concept. There's a reason for you to have it. An unprovoked is really...

probably those people on the Wells score who are scoring low and they actually come out with having PE because they haven't got any risk factors. They may have the clinical science side of it, but they haven't got the risk factors. And you're sort of sat there puzzling and said, have they just been unlucky, had a PE, or is there something that I'm not picking up? We'll come back to what we need to do about that in a minute. And so if you've got a provoked pulmonary embolism, the minimum treatment is three months for all pulmonary embolisms. But if you've got provoking PE and that risk factor has been removed, so you're now mobile, you're not still walking around, going on lots of holidays, you can stop the anticaragulation after three months.

most clinicians would carry it on for six. But there is a good study that's shown anticaragulation for three months versus six months versus 12 months has no effect on outcome. So actually, if you are somebody who's had three months of treatment for a PE, you've got no persisting risk factors and your risk of bleeding is higher than your average person, then we would probably consider stopping your anticaragulation for three months because there's no evidence that harms you. But on the other hand, if you've had an unprovoked and you've had treatment for three months, but you're... no risk of increased bleeding we may carry on for six months so it's three to six months okay but if you definitely have a first episode and it's unprovoked you've got so low bleeding nearly all of us will carry on your treatment for six months okay if there wasn't a contradiction and some people would continue continuing lifelong i was gonna say some are on lifelong aren't they but that's more often people who have another reason to be on anticoagulation so they've come in they've had a PE but we've also found them in AF so we've carried on for the AF stroke reduction or they've had a previous episode of VTE so if you have two or more we then recommend lifelong anticoagulation Okay, excellent. And so what are we moving on to now then? So the things I look for when I'm looking at patients in terms of risk of bleeding, for those people on anticoagulation, whether you decide whether they're a high risk of bleeding or low, we haven't got a scoring system like they have in atrial fibrillation of these that has lead at all, although it is actually pretty much the same sort of risk factors. So it's age over 75, a previous GI bleed, previous cerebrovascular accident, either ischemic or hemorrhagic, chronic kidney disease or liver disease, the concomitant administration of anticoagulants, or if they've got labile INRs or reliable monitoring, then they would be things that suggest you've got a higher than normal risk of bleeding. So you would consider three.

six months worth of treatment rather than longer treatments. I suppose the next thing that crops up is what do you do for those patients with unprovoked, to try and see whether there is anything else just causing it. So the stats are that 10% of people that have an unprovoked PE will develop an occult malignancy within the next five to 10 years. And actually that's front-weighted that actually the majority of those, so eight out of that, 80% of that 10% will develop malignancy within the first two years. So you're saying 8% of people with an unprovoked PE will end up having a malignancy.

So what should we do to see? Do we need to pick that up? Should we investigate? Is this the first presentation of a cancer we haven't previously diagnosed? So the NICE guidelines and the European Society of Cardiology guidelines suggest for everybody with a DTE, regardless of if it provokes or improvokes, who haven't got a history of cancer, they should all have a chest x-ray, a full blood count, a calcium and a liver function test done. They should all have a urinalysis done and they should have a directed physical examination. So for women that would be a breast exam, for men that would be a breast exam and a PR examination for prostate as well.

and that's for everybody, no cancer, not only have provokes or unprovokes. The chest x-ray is for the DVT patients, because obviously we'd have done a CTPA, so they don't need an x-ray if they've already had a CTPA. doing a second imaging modality that's not quite as accurate. Absolutely. The FBC would be to look for a hematological disease, thrombocytosis. The calcium would be to look for hypercalcemia relative to malignancy. And the low function would be to look for derailability from other meds or a primary. Yeah, exactly. And interesting, for those people that have got an unprovoked VTE who are over the age of 40 years, the guideline said that we should consider a CT abdo pelvis and mammography for women. So there's a lot of debate here, and I was talking to a couple of my colleagues today about what they do in their clinical practice.

Some people do do CT apoptosis, some people do ultrasounds. There was a study that looked at CT versus ultrasound for picking up these, and there was no difference between the pick-up rates. Some people don't do either of those things. I think it's very much clinician-based. I have had colleagues who have done CTs and have picked up four consecutive renal cell carcinomas in patients. They had an award in four consecutive patients with PE. So I think probably your experience flavours a little bit of what you do. But it's something to know about that. If you've got someone over 40 who's got a number of PE, you should be thinking about doing some further tests, and they should be consideration of some abdominal imaging of some sort. The guidelines would say consider CT and a mammography for women.

Very loosely phrase that, consider, isn't it? Yeah, that's the debate that we all have. Because the pick-up rate is probably somewhere between 1% and 5% for everybody with PE. But then if you're saying that 8% of people will develop in malignancy within two years, it's difficult to know what proportion of those are present at diagnosis and what develops two years later. So this isn't evidence-based. This was just a conversation myself and one of the other research fellows I was having earlier was, you know, it'd be nice to know if there was any evidence to delay the CT scan. So do the initial workup, treat them, but then six months or a year later do a CT and see what you pick up there. There's no evidence for that. That's just postulating and having a chair. So you've got to sit there in your clinic and tell the patient.

these facts to the face, as opposed to, you know, you think. Yeah, I mean, I don't know about you, Jamie, but we're in an age of very much shared decision making. And part of our job is, when needed to, stepping in and just doing what's needed for the patient, you know, when they're very sick or they can't make decisions themselves. But a lot of what we do now is communicating the evidence behind what we suggest they do and asking their opinion and doing some shared decision making. I think these investigations and treatments, especially...

decisions over anticoagulation, decisions over scan not to scan, decisions over duration, they're very much a shared decision making process where you present the risks of doing one thing and the risk of not doing one thing against another and you come up with a decision together and I think that's the best way to practice medicine and it's not paternalistic as it used to be. It can be frustrating sometimes but within those challenges you sort of learn new skills as well. And then so finally what would you like to talk about? So last thing for me really is covering pulmonary embasome pregnancy. So working on the acute take as a medical reg, being a respiratory reg, something you guys will see in ED, not frequently will be the pregnant lady or the postpartum lady who comes in, who's breastfeeding, who's short of breath, or who's got chest pain, or palpitations, or a bit of presyncope. And everybody always thinks of PE. It's a bit of a minefield, because you can't do the things you would traditionally do. So the Wells score for low-risk, high-risk works pretty well, and it's still validated. The problem is the D-dimer is rubbish. It doesn't tell you your arm for your ankle, and it's not validated. It shouldn't be done.

And so my approach to these people is taking a good history, doing a risk stratification. convincing them that actually doing an x-ray is very little harm to them and their unborn child to rule out everything else. And then if I need to, think about what is the best investigation and treatment for them in terms of diagnosing a PE. So I suppose a chest x-ray for the foetus is less than 0.01 millisieverts of radiation. It's very little. So tiny. And for the maternal breast tissue, which is what we really worry about with any radiological intervention, a young lady, is also 0.01 millisieverts. So the chest x-ray is a tiny amount. A VQ scan is approximately 1 millisievert risk to the foetus and about 1.2 millisieverts to the mother.

Now the good thing about VQ scanning is you can drop the ventilation side and just do the perfusion side in somebody who's got a normal x-ray. And so actually that gives you a 0.6 millisievert risk. So you can further reduce it when you're dealing with a breastfeeding or pregnant. Exactly. And a CTPA gives you about half a millisievert for the foetus, but between 10 and 70 millisieverts for a woman. And actually that is a significant risk to them in a 20, 30, 40 year old lady in terms of their lifetime risk of breast cancer. The numbers are somewhere between 1 in 200 and 1 in 2,000.

will develop breast cancer as a result of that radiological investigation. So it's not insignificant. If you've got a 1 in 200 risk, you've got to scan 200 women to give them one of them breast cancer in the future. So it's something to think about. Out of interest, what we call a danger threshold for a fetus. So that would be something that would be fatal for fetus in terms of radiation. It's considered to be 50 mS. So a CTPA at 0.5 is still...

100 times less than that dose. And a VQ scan at one millisecond, it's got 50 times less. There is a very small theoretical risk for a thetis of a VQ scan of future risk of hematological malignancy, specifically leukemia. But it's tiny. It's in the order of ones of hundreds of thousands to later life. So it's very, very low risk. So I suppose the approach is treat a pregnant lady as you treat anyone else. Don't do a D-dimer. And the guidance would suggest bilateral leg ultrasounds.

but also a VQ scan to then do the diagnosis. And the reason they do bilateral leg ultrasound is if you've got a DVT in a lady, you're going to treat her the same way, and just presume they've got a PE if they've got symptoms. So if they're hemodynamically stable, it's kind of academic. You know you've got a DVT, you may well have a PE. It's still the same treatment. Well, you're going to anticoagulant for the duration of their pregnancy, for the three months after their pregnancy, and then you're going to anticoagulant for any subsequent pregnancy, regardless of whether it's a DVT or PE. So there's no benefit in diagnosing a PE over DVT. Obviously, that's different if they're in a massive PE situation, cardiorespiratory compromised.

that then you need to, if they're peri-arrest or arresting, is obviously emergency cesarean section. You'd have to deliver the baby in the placenta and then treat them with thrombolysis and all the things that come with that. Actually, there may be something you need surgical embolectamine or a different treatment because if you've just done a massive surgery, they're in a high-risk population. And then the treatment for the peri-mariners we alluded to already is, you know, no molecular weight heparin, one milligram per kilogram, twice daily based on their booking weights. And you can adjust that treatment based on anti-10A measures.

we don't tend to get things like warfarin because they're teratogenic. Absolutely. And you always need to think about the implications when the mother's nursing, breastfeeding, of these medications as well. And I don't know, is it something that if a mother, if a woman has a PE during her pregnancy, say it's her first pregnancy, would you in clinic advise not getting pregnant again? No, we'd never advise them not to. We would want to know, well, we would want to know, the obstetricians would want to know when they got pregnant, if they got pregnant, because they would be anticoagulated for their subsequent pregnancies. And it's not licensed for the direct oral anticoagulants at the moment, so they're pretty much left with a subcut headroom.

Nine months injecting yourself. So it's a risk balance, but the majority you would end up antivagulating in future preferences. One thing we'd have mentioned is IVC filters. Yes. I suppose if we're failing with medical recurrent PEs, the good old-fashioned inferior vena cable filter. Yes. Still something that we do much of? Yes and no. It's mainly in people who have significant contraindications to pharmacological therapy. And actually a number of the filters that you put in are actually

Good at reducing PEs, but increase your risk of DVTs. And actually the advice is that you should still be anticoagulated on the filters anyway. So the situations you put them in is if somebody's just had surgery, they've got a lower limb DVT, you diagnose them with PE, they can't be anticoagulated because they've had a triple A repair, and you end up, well, triple A repair's probably a bad choice because you want to put a filter in, but you've had a hemicolectomy for cancer within a couple of days, they've got a PE, you think about doing a filter to prevent their risk of a large PE and mortality associated with that, but they probably still get worsening problems with DVT. You have to eventually either retrieve that device or anticoagulate them, and there are problems with device migration, depending on the site that you place. them within the venous the IVC or the SVC when they migrate there can be problems with clotting and thrombosis and the lack of venous and arterial return and so they're not in and of themselves a solution for all ills we've seen them used they're often considered in difficult cases they are what they are normally talk to a hematologist respiratory physician and liaised with interventional radiologists and between that group of people there's usually a consensus on who we should and shouldn't be doing those things to

Thank you very much. I think it's fair to say this is an absolute minefield. And it's somewhere that we need to know the data and we need to know what we need to do. And if in doubt, refer and talk to a friend or a senior. These are bits we can't really cover today, but one of the respiratory consultants here, Dr Lejeune, recently gave a talk here in A&E. There's all manner of new areas of research looking at age-related D-dimers so that actually the decade of your life, your D-dimers will go up naturally, so maybe we should be looking at that. That's something else that we're looking for in the future. The use of interventional radiology standardised in these young people with submassive PEs as a way of preventing pulmonary hypertension in the future. People listening to this who may still be at med school, this is going to be something that's going to change within their careers. It's something we need to stay current.

Well, there's an expanding field of research within acute pulmonary embolism, but also chronic thromboembolic pulmonary hypertension. You know, the guys at Sheffield, there's new and wonderful treatments for that coming out all the time, you know, embolectomies and catheter-related treatments for pulmonary hypertension and CTEF, and it's just an expanding field of research. And with the age of personalised medicine, like you say, there's been lots of developments coming up, so it's a hot topic, it's a common presentation, it's potentially a life-threatening presentation, it's something you've all got to know about. Thank you so much, Harry. You're welcome. Thank you very much, listeners. Bye-bye. That was the Take Orally PE podcast. Be sure to check out takeorally.com and you can also find us on both Facebook and Twitter. For more information about research and education opportunities within emergency medicine, acute medicine and major trauma, you can find A New Age Dream on both Facebook and Twitter.

Frequently asked questions

How long is this episode of Take Aurally?

This episode is 1 hour and 0 minutes long.

When was this Take Aurally episode published?

This episode was published on December 1, 2017.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Take Aurally episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.